Measuring and managing cognitive impairment in HIV

Area of Science:

• Neuroscience
• Infectious Diseases
• Pharmacology

Background:

• Cognitive impairment is a common issue for HIV-positive individuals, even with effective antiretroviral therapy (ART).
• Prevalence rates of cognitive impairment in treated HIV cohorts vary based on diagnostic criteria.
• The pathogenesis is complex, involving immune activation, neuroinflammation, ART neurotoxicity, comorbidities, and lifestyle factors.

Purpose of the Study:

• To explore the multifactorial nature of cognitive impairment in HIV-positive patients on ART.
• To examine how aging affects the contributing factors to cognitive decline in this population.
• To review current strategies for modifying ART in HIV-associated cognitive impairment.

Main Methods:

• Review of existing literature on HIV-associated cognitive impairment.
• Analysis of factors contributing to cognitive decline in aging HIV-positive populations.
• Discussion of cerebrospinal fluid (CSF) HIV RNA escape and its implications.

Main Results:

• Cognitive impairment in HIV is multifactorial, with contributions from neuroinflammation, comorbidities, and lifestyle.
• Aging populations with HIV may experience increased cerebrovascular and neurodegenerative contributions to cognitive impairment.
• CSF HIV RNA escape occurs in a subset of patients and can indicate compartmentalized resistance.

Conclusions:

• ART modifications for cognitive impairment should consider viral resistance and drug neurotoxicity.
• The optimal management of ART in the absence of clear resistance or neurotoxicity requires further investigation.
• Well-designed randomized trials are needed to guide ART changes in HIV-associated cognitive impairment.